English EN Spanish ES French FR Chinese (Simplified) ZH-CN
Print Friendly, PDF & Email

NCT/Study#

NCT04468984 /

M20-178

Abbvie, Protocol: M20-178, PI: Dr. Mccloskey, A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy And Safety Of Navitoclax In Combination With Ruxolitinib Versus Best Available Therapy In Subjects With Relapsed/Refractory Myelofibrosis (TRANSFORM-2)

DISEASE GROUP:
Leukemia
current phase:
Phase III
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: